No Data
No Data
New Data to Be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business
Analysts Have Conflicting Sentiments on These Healthcare Companies: Castle Biosciences (CSTL), AbCellera Biologics (ABCL) and Apellis Pharmaceuticals (APLS)
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $44
BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40
What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?